Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment
By Sabela Ojea
Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment.
At 9:43 a.m. ET, shares were up 21% at $3.83. The stock has, however, dropped 75% in the past 12 months.
The clinical-stage cell and gene therapy company said its early P-BCMA-ALLO1 clinical results inspire it to further develop the treatment for relapsed-refractory multiple myeloma in partnership with Roche.
Last year, Poseida said it signed a strategic collaboration with the biotechnology company Roche.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 11, 2023 10:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk